Phase 3, Multicenter, Randomized, Double-blind, Group Sequential, Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age

• ClinicalTrials.Gov
• View Study

AbbVie H20-012 PROSPECT – Parkinson’s Study

---

A prospective observational study to evaluate the clinical outcomes and burden of disease of PD patients with motor fluctuations not adequately controlled by current PD medications.

• Link not available
• View Study

Otsuka Pharmaceutical 20-AVP-786 ASPECT – Agitation in Alzheimer’s Study

---

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients

• ClinicalTrials.Gov
• View Study

Novartis LOU64C12302 – MS Study

---

A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib

• ClinicalTrials.Gov
• Study Not Available